Nurix Therapeutics, Inc. Quarterly General and Administrative Expense in USD from Q3 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary
Nurix Therapeutics, Inc. quarterly/annual General and Administrative Expense history and growth rate from Q3 2019 to Q3 2024.
  • Nurix Therapeutics, Inc. General and Administrative Expense for the quarter ending August 31, 2024 was $11.7M, a 10.3% increase year-over-year.
  • Nurix Therapeutics, Inc. General and Administrative Expense for the twelve months ending August 31, 2024 was $46M, a 10.9% increase year-over-year.
  • Nurix Therapeutics, Inc. annual General and Administrative Expense for 2023 was $42.9M, a 12.9% increase from 2022.
  • Nurix Therapeutics, Inc. annual General and Administrative Expense for 2022 was $38M, a 21.8% increase from 2021.
  • Nurix Therapeutics, Inc. annual General and Administrative Expense for 2021 was $31.2M, a 91.3% increase from 2020.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $46M $11.7M +$1.1M +10.3% Jun 1, 2024 Aug 31, 2024 10-Q 2024-10-11
Q2 2024 $44.9M $11.7M +$32K +0.27% Mar 1, 2024 May 31, 2024 10-Q 2024-07-11
Q1 2024 $44.9M $11.8M +$1.98M +20.1% Dec 1, 2023 Feb 29, 2024 10-Q 2024-04-10
Q4 2023 $42.9M $10.8M +$1.41M +15.1% Sep 1, 2023 Nov 30, 2023 10-K 2024-02-15
Q3 2023 $41.5M $10.6M +$875K +8.98% Jun 1, 2023 Aug 31, 2023 10-Q 2024-10-11
Q2 2023 $40.6M $11.7M +$2.02M +21% Mar 1, 2023 May 31, 2023 10-Q 2024-07-11
Q1 2023 $38.6M $9.82M +$593K +6.43% Dec 1, 2022 Feb 28, 2023 10-Q 2024-04-10
Q4 2022 $38M $9.37M +$549K +6.23% Sep 1, 2022 Nov 30, 2022 10-K 2024-02-15
Q3 2022 $37.4M $9.75M +$1.41M +16.8% Jun 1, 2022 Aug 31, 2022 10-Q 2023-10-12
Q2 2022 $36M $9.65M +$2.14M +28.5% Mar 1, 2022 May 31, 2022 10-Q 2023-07-13
Q1 2022 $33.9M $9.23M +$2.7M +41.3% Dec 1, 2021 Feb 28, 2022 10-Q 2023-04-13
Q4 2021 $31.2M $8.82M +$2.57M +41.1% Sep 1, 2021 Nov 30, 2021 10-K 2023-02-09
Q3 2021 $28.6M $8.34M +$4.01M +92.3% Jun 1, 2021 Aug 31, 2021 10-Q 2022-10-06
Q2 2021 $24.6M $7.51M +$4.24M +130% Mar 1, 2021 May 31, 2021 10-Q 2022-07-07
Q1 2021 $20.4M $6.53M +$4.08M +167% Dec 1, 2020 Feb 28, 2021 10-Q 2022-04-08
Q4 2020 $16.3M $6.25M Sep 1, 2020 Nov 30, 2020 10-K 2022-01-28
Q3 2020 $4.34M +$2.15M +98.6% Jun 1, 2020 Aug 31, 2020 10-Q 2021-10-14
Q2 2020 $3.27M Mar 1, 2020 May 31, 2020 10-Q 2021-07-13
Q1 2020 $2.45M Dec 1, 2019 Feb 29, 2020 10-Q 2021-04-13
Q3 2019 $2.18M Jun 1, 2019 Aug 31, 2019 10-Q 2020-10-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.